The project will be instrumental in enhancing the company's API manufacturing capacity and global reach
This strategic expansion marks a significant step in the company's global growth strategy
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments
BioNTech and Bristol Myers Squibb will jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types
The newly launched protocol will accelerate the clinical development of stenoparib and its drug-specific Drug Response Predictor (DRP) companion diagnostic (CDx) toward potential FDA approval
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Subscribe To Our Newsletter & Stay Updated
